secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2023-05-18T23:59:59+00:00
Accession:  0000950170-23-022879
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen announces positive Phase 3 results for roxadustat in chemotherapy-induced anemia in China
--------------------------------------------------------------------------------

- Met primary endpoint: noninferiority to erythropoietin alfa in hemoglobin change from baseline to average weeks 9-13.
- Plan to file supplemental New Drug Application in China with AstraZeneca collaboration.
- 159 non-myeloid malignancy patients enrolled; roxadustat dosed three times weekly for 12 weeks.
- Adverse event profile consistent with prior studies, supporting positive benefit-risk.
- Detailed results to be presented at an upcoming medical conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017023022879/0000950170-23-022879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017023022879/fgen-20230518.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-022879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer